Form 8-K Filing - AbbVie Inc.

AbbVie Inc. reported preliminary results for the first quarter of 2026, expecting acquired IPR&D and milestones expense of $744 million on a pre-tax basis. This is anticipated to negatively impact both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share by $0.41. The company has updated its full-year 2026 adjusted diluted earnings per share guidance to a range of $13.96 - $14.16, and the first quarter 2026 adjusted diluted earnings per share guidance to $2.56 - $2.60, inclusive of the first quarter's acquired IPR&D and milestones expense. AbbVie does not forecast acquired IPR&D and milestones expense due to the uncertainty of future transactions. Forward-looking statements in the report are subject to risks and uncertainties that could cause actual results to differ materially.